Numerous models have been developed to study ocular neovascularization. One of the first, laser-induced choroidal neovascularization (CNV) was originally developed in primates 1 and later adapted to rodents. 2 This model has proven to be a robust tool for evaluating potential therapies for exudative AMD. Work using the laser-induced CNV model provided the critical proof of concept that paved the way for the development of photodynamic therapy, the first approved therapy for exudative AMD and subsequently the highly effective anti-VEGF treatments currently in use today.
